Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $361.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 9.39% from the stock’s current price.

A number of other research firms have also recently issued reports on KRYS. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price for the company. Finally, The Goldman Sachs Group started coverage on shares of Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $377.20.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded down $0.69 during trading on Thursday, reaching $330.00. The stock had a trading volume of 288,016 shares, compared to its average volume of 328,559. Krystal Biotech has a 52 week low of $183.03 and a 52 week high of $382.54. The business’s 50-day moving average price is $340.46 and its 200 day moving average price is $322.60. The stock has a market capitalization of $9.77 billion, a PE ratio of 41.35 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Analysts forecast that Krystal Biotech will post 7.47 EPS for the current year.

Insider Buying and Selling

In related news, Director Dino Rossi sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Silvant Capital Management LLC acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at $30,000. Integrated Wealth Concepts LLC acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at $46,000. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $34,000. USA Financial Formulas acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $44,000. Finally, GK Wealth Management LLC acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.